Novel immunomodulating agents for graves orbitopathy

Ophthalmic Plastic and Reconstructive Surgery

Volumn 24, Issue 4, 2008, Pages 251-256

  Bartalena, Luigi ^a   Lai, Adriana ^a   Compri, Emanuele ^a   Marcocci, Claudio ^b   Tanda, Maria Laura ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY INTERLEUKIN 6 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SOMATOSTATIN; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

AUTOIMMUNITY; CELL FUNCTION; ENDOCRINE OPHTHALMOPATHY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SMOKING; T LYMPHOCYTE; THYROID DISEASE; THYROIDECTOMY; IMMUNOLOGY; ORBIT DISEASE;

GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOLOGIC FACTORS; ORBITAL DISEASES;

EID: 48849087863     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/IOP.0b013e318179f8a5     Document Type: Review

References (51)

1. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000;21: 168-199 (Pubitemid 32275594)
2. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1995; 42:45-50.
3. Wiersinga WM, Prummel MF, Terwee C. Effects of Graves' ophthalmopathy on quality of life. J Endocrinol Invest 2004;27: 259-264 (Pubitemid 38607479)
4. Bartalena L, Marcocci C, Pinchera A. Graves' ophthalmopathy: a preventable disease? Eur J Endocrinol 2002;146:457-461
5. Bartalena L, Marcocci C, Pinchera A. Treating severe Graves' ophthalmopathy. Baillieres Clin Endocrinol Metab 1997;11:521-536
6. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158:273-285
7. Bartalena L, Marcocci C, Tanda ML, et al. An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest 2005;28:469-478 (Pubitemid 43162746)
8. Bahn RS. Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003;88:1939-1946
9. Feldon SE, Park DJJ, O'Loughlin CW, et al. Autologous Tlymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2006;46:3913-3921
10. Drexhage HA. Are more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves' disease? Endocrinology 2005;147:9-12.
11. Bahn RS, Dutton CM, Natt N, et al. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998;83:998-1002. (Pubitemid 28496482)
12. Agretti P, Chiovato L, De Marco G, et al. Real time PCR provides evidence for thyrotropin receptor mRNA expression in orbital as well as in extraorbital tissues. Eur J Endocrinol 2002;147:733-739 (Pubitemid 36032961)
13. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003;24:802-835 (Pubitemid 38067700)
14. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;23:2598-2608 (Pubitemid 41007846)
15. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54: 1763-1769 (Pubitemid 40770766)
16. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-1915 (Pubitemid 37409707)
17. Tontonor P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid activated transcription factor. Cell 1994;79:1147-1156
18. Starkey K, Heufelder A, Baker G, et al. Peroxisome proliferator-activated receptor-γ in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 2003;88:55-59 (Pubitemid 36115143)
19. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-1769 (Pubitemid 38725087)
20. Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1996;81:449-452
21. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. The effects of tumour necrosis factor-α and interleukin 1 on an in vitro model of thyroid-associated ophthalmopathy: contrasting effects on adipogenesis. Eur J Endocrinol 2006;155:395-403. (Pubitemid 44463945)
22. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab 2007;92:59-64. (Pubitemid 46067509)
23. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002;12:855-860
24. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-1068 (Pubitemid 39120355)
25. Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005;19:1286-1289 (Pubitemid 43148503)
26. Durrani OM, Reuser TQ, Murray IP. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005;24:117-119 (Pubitemid 40904566)
27. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295: 2275-2285 (Pubitemid 43736578)
28. Bartalena L, Tanda ML. Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying. J Endocrinol Invest 2006; 29:1012-1016 (Pubitemid 46344237)
29. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-535 (Pubitemid 41295078)
30. Nielsen H, El Fassi D, Hasselbach HC, et al. B-cell depletion with rituximab in the treatment of autoimmune diseases: Graves' ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther 2007;7:1061-1078
31. El Fassi D, Clemmensen O, Nielsen CH, et al. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. J Clin Endocrinol Metab 2007;92: 3762-3763
32. El Fassi D, Nielsen CH, Hasselbach CH, Hegedus L. Treament-resistant severe, active Graves' ophthalmopathy successfully treated by B lymphocyte depletion. Thyroid 2006;16:709-710 (Pubitemid 44246272)
33. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156:33-40. (Pubitemid 46553901)
34. Pasquali D, Vassallo P, Esposito D, et al. Somatostatin gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 2000;25:63-71. (Pubitemid 30617075)
35. Pasquali D, Notaro A, Bonavolontà G, et al. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissue in Graves' disease. J Clin Endocrinol Metab 2002;87:5125-5129 (Pubitemid 35316355)
36. Cozma I, Zhang L, Uddin J, et al. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs. Am J Physiol Endocrinol Metab 2007;293:E1630-E1635. (Pubitemid 350255113)
37. Kahaly GJ. Recent developments in Graves' ophthalmopathy imaging. J Endocrinol Invest 2004;27:254-258 (Pubitemid 38607478)
38. Colao A, Lastoria S, Ferone D, et al. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1998;83: 3790-3794 (Pubitemid 28513552)
39. Krassas GE. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 2004;27:281-287
40. Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004;89:5910-5915 (Pubitemid 39628391)
41. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005;90: 841-848 (Pubitemid 40279207)
42. Chang T-C, Liao S-L. Slow-release lanreotide in Graves' ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 2006;29:413-422 (Pubitemid 44043357)
43. Stan MN, Garrity JA, Bradley EA, et al. Randomized, doubleblind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 2006;91:4817-4824
44. Tanda ML, Bartalena L. Currently available somatostatin analogs are not good for Graves' orbitopathy. J Endocrinol Invest 2006; 29:389-390 (Pubitemid 44043352)
45. Gerding MN, van der Meer JWC, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2005;52:267-271
46. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91:3464-3470 (Pubitemid 44402120)
47. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-351 (Pubitemid 38124590)
48. Bartalena L, Marcocci C, Lai A, Tanda ML. Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid? J Endocrinol Invest. In press.
49. Moleti M, Mattina F, Salamone I, et al. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves' ophthalmopathy. Thyroid 2003;13:653-658 (Pubitemid 36993561)
50. Menconi F, Marinò M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007;92:1653-1658 (Pubitemid 46997167)
51. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-78 (Pubitemid 28042269)